Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort.

Ann Hematol · 2021 · PMC8043896 · PMID 33704530

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In this category, the median PFS differed between the patient, who received standard treatment (0.4 months), and the remaining patients receiving additional lenalidomide (2.6 months; p = 0.25), yet this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.